UM has received personal fees (as consultant and/or speaker bureau) from Boehringer Ingelheim, Roche, MSD, Amgen, Thermo Fisher Scientifics, Eli Lilly, Diaceutics, GSK, Merck and AstraZeneca, unrelated to the current work. CR reported receiving research grants at Antwerp University Hospital, Belgium, from Novartis and Sanofi, receiving speaker fees from Guardant Health, Merck Sharp & Dohme, and Novartis, receiving scientific advisor fees from Mylan, serving on a steering scientific committee for Oncompass, and participating in research collaborations for OncoDNA and Biomark Inc, unrelated to the current work. EG has received personal fees (as consultant and/or speaker bureau) from AstraZeneca, Boehringer Ingelheim, Bristol-Myers-Squibb, Eli Lilly, MSD, Novartis, Roche, Takeda, and research grants (institution) from AstraZeneca, Bristol-Myers-Squibb, and Roche. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.